Translational studies in older men using testosterone to treat sarcopenia

Randall Urban, Edgar Dillon, S. Choudhary, Yingxin Zhao, A. M. Horstman, Ronald Tilton, M. Sheffield-Moore

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Sarcopenia is the loss of skeletal muscle mass and strength that occurs with aging. Our research group has found an efficacious administration paradigm using testosterone to combat sarcopenia in humans. In addition, our research has uncovered an important regulatory enzyme of inflammation, nuclear factor-κB-inducing kinase that may regulate human skeletal muscle catabolism, and that appears to be counter-regulated by administration of standard doses of testosterone. This is important because a number of age-related clinical circumstances trigger acute and chronic muscle loss including cancer, chronic obstructive pulmonary disease, hospitalization, acute and chronic illness, and diseases in which systemic inflammation occurs. Moreover, it is often the treatment itself that can induce muscle loss. For example, glucocorticoids are tremendously effective at reducing inflammation and are a frontline therapy for many inflammatory-based diseases, yet paradoxically trigger muscle loss. We will discuss our research findings and the clinical significance of our human clinical translational research with testosterone.

Original languageEnglish (US)
JournalTransactions of the American Clinical and Climatological Association
Volume125
StatePublished - 2014
Externally publishedYes

Fingerprint

Sarcopenia
Testosterone
Inflammation
Muscles
Skeletal Muscle
Chronic Disease
Research
Translational Medical Research
Muscle Strength
Chronic Obstructive Pulmonary Disease
Glucocorticoids
Hospitalization
Phosphotransferases
Enzymes
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Translational studies in older men using testosterone to treat sarcopenia. / Urban, Randall; Dillon, Edgar; Choudhary, S.; Zhao, Yingxin; Horstman, A. M.; Tilton, Ronald; Sheffield-Moore, M.

In: Transactions of the American Clinical and Climatological Association, Vol. 125, 2014.

Research output: Contribution to journalArticle

@article{ab6989a5be8043f0ad58a1431570ce66,
title = "Translational studies in older men using testosterone to treat sarcopenia",
abstract = "Sarcopenia is the loss of skeletal muscle mass and strength that occurs with aging. Our research group has found an efficacious administration paradigm using testosterone to combat sarcopenia in humans. In addition, our research has uncovered an important regulatory enzyme of inflammation, nuclear factor-κB-inducing kinase that may regulate human skeletal muscle catabolism, and that appears to be counter-regulated by administration of standard doses of testosterone. This is important because a number of age-related clinical circumstances trigger acute and chronic muscle loss including cancer, chronic obstructive pulmonary disease, hospitalization, acute and chronic illness, and diseases in which systemic inflammation occurs. Moreover, it is often the treatment itself that can induce muscle loss. For example, glucocorticoids are tremendously effective at reducing inflammation and are a frontline therapy for many inflammatory-based diseases, yet paradoxically trigger muscle loss. We will discuss our research findings and the clinical significance of our human clinical translational research with testosterone.",
author = "Randall Urban and Edgar Dillon and S. Choudhary and Yingxin Zhao and Horstman, {A. M.} and Ronald Tilton and M. Sheffield-Moore",
year = "2014",
language = "English (US)",
volume = "125",
journal = "Transactions of the American Clinical and Climatological Association",
issn = "0065-7778",
publisher = "American Clinical And Climatological Association",

}

TY - JOUR

T1 - Translational studies in older men using testosterone to treat sarcopenia

AU - Urban, Randall

AU - Dillon, Edgar

AU - Choudhary, S.

AU - Zhao, Yingxin

AU - Horstman, A. M.

AU - Tilton, Ronald

AU - Sheffield-Moore, M.

PY - 2014

Y1 - 2014

N2 - Sarcopenia is the loss of skeletal muscle mass and strength that occurs with aging. Our research group has found an efficacious administration paradigm using testosterone to combat sarcopenia in humans. In addition, our research has uncovered an important regulatory enzyme of inflammation, nuclear factor-κB-inducing kinase that may regulate human skeletal muscle catabolism, and that appears to be counter-regulated by administration of standard doses of testosterone. This is important because a number of age-related clinical circumstances trigger acute and chronic muscle loss including cancer, chronic obstructive pulmonary disease, hospitalization, acute and chronic illness, and diseases in which systemic inflammation occurs. Moreover, it is often the treatment itself that can induce muscle loss. For example, glucocorticoids are tremendously effective at reducing inflammation and are a frontline therapy for many inflammatory-based diseases, yet paradoxically trigger muscle loss. We will discuss our research findings and the clinical significance of our human clinical translational research with testosterone.

AB - Sarcopenia is the loss of skeletal muscle mass and strength that occurs with aging. Our research group has found an efficacious administration paradigm using testosterone to combat sarcopenia in humans. In addition, our research has uncovered an important regulatory enzyme of inflammation, nuclear factor-κB-inducing kinase that may regulate human skeletal muscle catabolism, and that appears to be counter-regulated by administration of standard doses of testosterone. This is important because a number of age-related clinical circumstances trigger acute and chronic muscle loss including cancer, chronic obstructive pulmonary disease, hospitalization, acute and chronic illness, and diseases in which systemic inflammation occurs. Moreover, it is often the treatment itself that can induce muscle loss. For example, glucocorticoids are tremendously effective at reducing inflammation and are a frontline therapy for many inflammatory-based diseases, yet paradoxically trigger muscle loss. We will discuss our research findings and the clinical significance of our human clinical translational research with testosterone.

UR - http://www.scopus.com/inward/record.url?scp=84995699286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995699286&partnerID=8YFLogxK

M3 - Article

VL - 125

JO - Transactions of the American Clinical and Climatological Association

JF - Transactions of the American Clinical and Climatological Association

SN - 0065-7778

ER -